Substance / Medication

Ergotamine

Overview

Active Ingredient
ergotamine
RxNorm CUI
4025

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Dihydroergotamine (DHE) - Then and Now: A Narrative Review.
Silberstein Stephen D, Shrewsbury Stephen B, Hoekman John · Headache · 2020
PMID: 31737909Meta-AnalysisFull text (PMC)
Assessment of the consistency of absorption of dihydroergotamine following oral inhalation: pooled results from four clinical studies.
Kellerman Donald J, Forst Amy, Combs Daniel L et al. · J Aerosol Med Pulm Drug Deliv · 2013
PMID: 23273242Meta-Analysis
Where is dihydroergotamine mesylate in the changing landscape of migraine therapy?
Morren John A, Galvez-Jimenez Nestor · Expert Opin Pharmacother · 2010
PMID: 21080856Meta-Analysis
Parenteral dihydroergotamine for acute migraine headache: a systematic review of the literature.
Colman Ian, Brown Michael D, Innes Grant D et al. · Ann Emerg Med · 2005
PMID: 15795718Meta-Analysis
Modulatory effect of the 5-HT1A agonist buspirone and the mixed non-hallucinogenic 5-HT1A/2A agonist ergotamine on psilocybin-induced psychedelic experience.
Pokorny Thomas, Preller Katrin H, Kraehenmann Rainer et al. · Eur Neuropsychopharmacol · 2016
PMID: 26875114RCT
MAP0004, orally inhaled dihydroergotamine for acute treatment of migraine: efficacy of early and late treatments.
Tepper Stewart J, Kori Shashidhar H, Goadsby Peter J et al. · Mayo Clin Proc · 2011
PMID: 21964172RCTFull text (PMC)
Ergotamine and triptans induced medication-overuse headache: a real-world population-based comparative study from the Northern Thai headache registry.
Tanprawate Surat, Thiankhaw Kitti, Chusilthong Watthikorn et al. · J Headache Pain · 2025
PMID: 41039192ObservationalFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ergotamine (substance)
SNOMED CT
395975005
UMLS CUI
C0014710
RxNorm CUI
4025

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.